Consensus BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
144.1 ^USD	+3.59%		+9.30%	-20.09%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Evolution of the average Target Price on BeiGene, Ltd.

Price target over the last 5 years

History of analyst recommendation changes

636ef7772d2c580c0d52b7e952dfde.fVjySO2CgIZFEAa9mxzReJOOmAAYaRrBG571YeJ-d-E.MyHCAa7xuO0PY2qO42S2QP3BwGNLWXCSXaitG5ERNtMSK4d5rs30sBxlNg~7d5b426c60f35a3becdca9b6e250e57e

Analyst Recommendations on BeiGene, Ltd.

BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy	Feb. 22	MT
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating	Nov. 07	MT
Citigroup Lowers Price Target on BeiGene to $285 From $290, Maintains Buy Rating	23-10-26	MT
Future Rate Hike Fears Bring Hong Kong Stocks to Slump; BeiGene Slips 7%	23-09-21	MT
Citigroup Raises BeiGene Price Target to $290 From $285, Maintains Buy Rating	23-09-20	MT
Macquarie Starts BeiGene at Outperform, $259 Price Target	23-09-12	MT
Morgan Stanley Adjusts BeiGene's Price Target to $319 From $321, Keeps Overweight Rating	23-08-29	MT
Jefferies Starts BeiGene at Buy With $287 Price Target	23-08-17	MT
JPMorgan Chase Adjusts Price Target on BeiGene to $300 From $297, Maintains Overweight Rating	23-08-07	MT
Nomura Adjusts BeiGene Price Target to $253.14 From $309.47, Maintains Buy Rating	23-07-20	MT
Nomura Adjusts BeiGene's Price Target to HK$152.86 From HK$186.87, Keeps at Buy	23-07-20	MT
Citigroup Initiates BeiGene With Buy Rating, $275 Price Target	23-07-17	MT
Bernstein Downgrades BeiGene to Market Perform From Outperform, Cuts Price Target to $196 From $335	23-06-30	MT
Nomura Adjusts BeiGene's Price Target to HK$186.87 From HK$172.81, Keeps at Buy	23-05-05	MT
Nomura Adjusts BeiGene Price Target to $309.47 From $286.19, Maintains Buy Rating	23-05-05	MT
Morgan Stanley Adjusts Price Target on BeiGene to $321 From $325, Maintains Overweight Rating	23-02-28	MT
Cowen Adjusts Price Target on BeiGene to $262 From $213, Maintains Outperform Rating	23-02-28	MT
Nomura Adjusts BeiGene's Price Target to $286.19 From $281.78, Maintains Buy Rating	23-02-23	MT
Nomura Adjusts BeiGene's Price Target to HK$172.81 From HK$170.15, Keeps at Buy	23-02-23	MT
Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight Rating	23-01-24	MT
Guggenheim Raises Price Target on BeiGene to $350 From $290, Maintains Buy Rating	23-01-20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

144.1 USD

Average target price

268.7 USD

Spread / Average Target

+86.43%

High Price Target

345 USD

Spread / Highest target

+139.38%

Low Price Target

161 USD

Spread / Lowest Target

+11.71%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BeiGene, Ltd.

Bernstein
Nomura
Citigroup
Macquarie
Morgan Stanley
Jefferies & Co.
JPMorgan Chase
Cowen
SVB Securities LLC
Guggenheim
CMB International
SVB Leerink
Goldman Sachs
HSBC
China Renaissance
CLSA

Ratings for BeiGene, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar